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Objective(s): Paraoxonase-1 (PON1), an HDL-associated enzyme, prevents lipoprotein oxidation. PON1 enzymatic
activity has been shown to decrease in patients with diabetes. Paraoxonase activity. HDL capacity to bind with
PON1 is possible under specific experimental conditions, such as oxidation, addition of polyphenols, or in diabetic
patients with polyphenols doses. The aim of this study was the effect of pomegranate juice (PJ) on paraoxonase
and arylesterase activity of PON1.
Materials and methods: Fifty patients with type 2 diabetes mellitus consumed 200 ml of PJ daily for a period of
6 weeks. Blood was collected from the patients before and after PJ consumption after 12 h of fasting. Blood sugar,
total cholesterol, triglyceride, LDL- C and HDL-C were measured by colorimetric kit method. The malondialdehyde
concentration (μmol/L) was determined by thiobarbituric acid (TBA) assay. Paraoxonase and arylesterase activity of
PON1 enzyme were measured using paraoxone and phenylacetate as the substrates.
Results: The concentration of fasting blood sugar, total cholesterol, LDL-C and malondialdehyde significantly
(p < 0.001) decreased after the intervention. Paraoxonase and arylesterase activity of PON1 significantly (p < 0.001)
increased after the intervention. There were however no significant changes in serum triglyceride and HDL-C. There
was a significant positive correlation between paraoxonase and arylesterase activity of PON1 and serum HDL-C
concentration . A significant negative correlation was detected between paraoxonase and arylesterase activity of
PON1 and FBS.
Conclusion: It can be concluded that PJ consumption as an antioxidant may have a contribution in changing
fasting blood sugar, lipid profiles, lipoprotein oxidation, and PON1 activity.
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Paraoxonase (EC.3.1.8.1, aryldialkylphosphatase) has
been extensively studied in the field of toxicology [1].
Paraoxonase hydrolyzes organophosphate compounds,
are widely used as insecticides and nerve gases [2,3].
Human serum paraoxonase (PON1) is synthesized in
the liver and is physically associated with HDL, on
which it is almost exclusively located. Several studies
have indicated that PON1 can prevent lipid peroxide ac-
cumulation on LDL both in vitro and in vivo [4,5].
Some studies have shown that serum PON1 activity is* Correspondence: n_ parsaeyan@yahoo.com
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reproduction in any medium, provided the orreduced in diabetes [6-17]. Recently, studies in PON1
demonstrated that PON1 has a protective role against dia-
betes development, secondary to its unique antioxidant
properties [13]. The high concentrations of glucose in
diabetic serum could account for PON1 dissociation from
HDL [14]. Paraoxonase activity is under both genetic and
environmental influences and varies widely among indivi-
duals [11].
Among the main risk factors responsible for coronary
heart disease (CHD), diet has an important role in
patients with diabetes as well, because it regulates the
levels of plasma lipids and lipoproteins, blood pressure,
energy balance, thrombogenesis, and the oxidative modi-
fication or protection of plasma lipids and lipoproteins
[15]. PJ contains polymolecular ellagitannin compounds,
such as punicalagin, which is a potent antioxidantral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Mean concentration and standard deviation of
fasting blood sugar (FBS), lipids, lipoprotein and
malondialdehyde in patients with type 2 diabetes before
and after pomengranate juice consumption
Biochemical parameters Before After P-value
Mean± SD Mean± SD
FBS(mg/dl) 195.38± 31.91 160.64 ± 37.47 <0.001
TC(mg/dl) 179.02± 29.16 160.04 ± 11.98 <0.001
TG(mg/dl) 169 .64 ± 10.70 162.08 ± 9.02 0.05
HDL-C(mg/dl) 36.58 ± 4.60 38.36 ± 5.56 0.98
LDL-C(mg/dl) 101.29± 15.78 85.12 ± 13.94 <0.001
MDA(μmol/L) 0.073 ± 0.046 0.029 ± 0.021 <0.001
FBS = fasting blood sugar, TC = total cholesterol TG = triglyceride, HDL-C = high
density lipoprotein cholesterol, LDL-C = low density lipoprotein cholesterol,
MDA=malondialdehyde.
Table 3 Correlation between paraoxonase activity and




Paraoxonase activity Arylesterase activity
r p-value r p-value
FBS(mg/dl) −0.690 0.000 −0.718 0.000
TC(mg/dl) −0.234 0.270 −0.090 0.67
TG(mg/dl) −0.071 0.74 −0.054 0.80
HDL-C(mg/dl) 0.451 0.027 0.622 0.001
LDL-C(mg/dl) −0.245 0.249 −0.040 0.854
MDA(μmol/L) −0.432 0.021 −0.502 0.035
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sumption of PJ by patients with diabetes decreases oxi-
dative stress in their serum and contributes to PON1
stabilization, increases PON1 association with HDL, and
stimulates the enzyme catalytic activities [18,19]. The
aim of the present study was to determine the effect of
PJ consumption on paraoxonase enzyme activity in
patients with type 2 diabetes.
Materials and methods
In this quasi-experimental interventional study, fifty
patients with type 2 diabetes mellitus, consumed 200 ml
of PJ daily for a period of 6 weeks. The patients served
as their own controls because we compared all data after
the pomegranate consumption with the baseline values.
The patients in the study had no hypertension and car-
diovascular diseases. None of the participants received
any antioxidant supplementations in the past 3 months.
They followed their own normal diet. PJ was prepared
from the whole fruit after being cut and exposed to arils
for the squeezing process. The juice was then filtered,
pasteurized, concentrated and stored at −18°C. The con-
centrated PJ was diluted 1:4 (v:v) to 16 Brix (Brix is a
measurement of soluble solids in fruit juice and repre-
sents the sugars and many other soluble substances such
as salts, acids, and tannins. Brix is measured in grams
per hundred milliliter) with water to obtain a single-Table 2 Mean concentration and standard deviation of the pa
ratio in patients with type 2 diabetes before and after pomen
Enzyme activity Before
Mean± SD
Paraoxonase activity (μmol/L) 135.02 ±104.14
Arylesterase activity (μmol/L) 165.02 ± 56.63
Aaraoxonase/arylesterase 1.22 ± 0.54strength PJ to be used in the study. Blood was collected
from the patients before and after PJ consumption after
12 h of fasting. Serum was then separated, and fasting
blood sugar (FBS), total cholesterol, triglyceride and
HDL-C were measured by enzymatic and colorimetric
kit method . The concentration of LDL-C was calculated
by using Friedwald formula. The malondialdehyde con-
centration (μmol/L) was determined by thiobarbituric
acid (TBA) assay. Paraoxonase activity (μmol/L) was
measured by adding 20 μL serum to 700 μL buffer
[2 mmol/L paraoxone, 2 mmol/L Cacl2 in 1 mmol/L
Tris–HCl buffer (PH= 8)] and then Para-nitrophenyl as
a product was measured at 412 nm wavelength. Also ary-
lesterase activity of PON1 was measured by using 10 μL
serum and mixture of 2 mmol/L phenylacetate and
2 mmol/L Cacl2 in 100 mmol/L Tris–HCl buffer (PH=8).
Then hydrolysis rate of phenylacetate at wavelength
270 nm was measured by spectrophotometer.
Results
The ratio of male to female patients was nearly the
same. The patients, mean age was 45 ± 8y and the mean
for their BMI was 30 ± 3 kg/m2 . Table 1 shows the com-
parison of serum lipids, lipoproteins and malondialde-
hyde before and after PJ consumption. As shown in
Table 1 mean of FBS, total cholesterol, LDL-C and
malondialdehyde decreased significantly (p < 0.001) after
the intervention. There were however no significant
changes in serum triglyceride and HDL-C concentration.




225.18 ± 149.52 <0.001
246.36 ± 49.26 <0.001
1.94 ± 0.32 <0.001
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Para-oxonase and aryl esterase activity of PON1 and
their ratio increased significantly after the intervention
(p <0.001). Also the correlation between paraoxonase
activity and arylesterase activity of PON1 and other bio-
chemical parameters revealed a positive correlation be-
tween paraoxonase and arylesterase activity of PON1
and serum HDL-C concentration which was statistically
significant. A significant negative correlation was detected
between paraoxonase and arylesterase activity of PON1
and FBS (Table 3).
Discussion
Pomegranate is an important source of bioactive com-
pounds and has been used in traditional medicine for
centuries. PJ is known to be high in antioxidant activity
[15-19]. The present study was designed to evaluate the
effect of PJ on FBS, lipid profiles, lipid oxidation PON1
paraoxonase activity, arylesterase activity of PON1 and
their correlation in patients with type 2 diabetes. Our
results showed that daily consumption of 200 ml PJ
decreased the mean of FBS, total cholesterol, LDL-C and
malondialdehyde significantly (p <0.001). There were
however no significant changes in serum triglyceride and
HDL-C concentration. The results of this study are in
line with that of M.I. Gil et al. They reported that con-
sumption of PJ in patients with type 2 diabetes decreases
cholesterol and LDL-C concentration [15]. Esmailzadeh
A. et al. have shown significant reduction of total choles-
terol (P <0.006), LDL-C (P <0.006), LDL-C/HDL-C
(P <0.001), and total cholesterol/HDL-C (P <0.001) after
8 weeks of PJ consumption in patients with diabetes.
There were however no significant changes in serum
triacylglycerol and HDL-C concentrations [16].
In this study, mean of paraoxonase and aryl esterase
activity of PON1 and their ratio were increased signifi-
cantly after the intervention (p < 0.001). This indicated
that polyphenols compounds in PJ have antioxidant effect.
Rosenblat. M. et al. reported that PJ consumption results
in a significant reduction of thiobarbituric acid reactive
substances (TABARS) and an increase in PON1 activity
thus being in line with that of our study [18,19]. Yukio
Ikeda et al. and other investigators have shown that PON1
levels decrease in patients with diabetes [6-17].
PJ increased PON1 activity because its components
(tannins and anthocyanin) have direct effect on enzyme
activity [15]. In this study the correlation between para-
oxonase activity and arylesterase activity of PON1 and
other biochemical parameters showed that there is sig-
nificant positive correlation between paraoxonase and
arylesterase activity of PON1 and serum HDL-C concen-
tration (r = 0.451 p = 0.027, r = 0.622 p = 0.001). Also
there is a significant negative correlation between para-
oxonase and arylesterase activity of PON1 and FBS(r = 0.69 p < 0.001, r = 0.718 p < 0.001). Measurment of
PON1 enzyme activity, evaluation of changes in its per-
formance in patients with type 2 diabetes and managing
PJ supplement were the new and positive points of this
research. Measurment of just one antioxidant enzyme
was the negative aspect of the study. Therefore more ex-
tensive studies have to be carried out on PON1 enzyme
for the management of diabetes.
Conclusion
These results demonstrated that PJ consumption for
6 weeks may exert beneficial effects on fasting blood
sugar, lipid profiles, lipoprotein oxidation and PON1 ac-
tivity. The juice therefore can have more potential as a
health supplement rich in normal antioxidant.
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